As of June 2, 2025, Danameco Medical Joint Stock Corp (DNM.VN) reports a ROE (Return on Equity) of -5.95%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Danameco Medical Joint Stock Corp's ROE (Return on Equity)
Over recent years, Danameco Medical Joint Stock Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -5.95% |
| 2023-12-31 | -1029.41% |
| 2022-12-31 | -140.45% |
| 2021-12-31 | 20.91% |
| 2020-12-31 | 30.45% |
This slight downward trend highlights how Danameco Medical Joint Stock Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Danameco Medical Joint Stock Corp's ROE (Return on Equity) to Peers
To better understand Danameco Medical Joint Stock Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Danameco Medical Joint Stock Corp (DNM.VN) | -5.95% |
| Thai Optical Group PCL (TOG.BK) | 17.62% |
| RAYBAN SUN OPTICS INDIA Pvt Ltd (BAUSCHLOMB.NS) | 15.10% |
| Metabiomed Co Ltd (059210.KQ) | 14.39% |
| Mohini Health & Hygiene Ltd (MHHL.NS) | 13.82% |
| SciVision Biotech Inc (1786.TW) | 12.77% |
Compared to its competitors, Danameco Medical Joint Stock Corp's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.